Notice for Teprotumumab (Amgen Australia Pty Ltd)
Active ingredients
Teprotumumab
Sponsor
Date of review outcome
Lapse date
Type
Priority Review
Indication
Treatment of thyroid eye disease
Therapeutic area
Endocrinology